NCT00455351已完成1 期
Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.
Oslo University Hospital1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2007年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- DLT
研究概览
简要总结
Phase I study. Side-effects when combined with standard palliative radiotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pelvic malignancy
- •Palliative radiation treatment planed
- •Age>18 years
排除标准
- •Previous pelvic radiotherapy
- •Uncontrolled diarrhea
- •Insulin-dependent diabetes mellitus
- •BMI<18.5
研究组 & 干预措施
A I
Experimental
Study drug
干预措施: Vorinostat (Drug)
结局指标
主要结局
DLT
时间窗: continously
次要结局
未报告次要终点
研究者
Svein Dueland
Senior physician
Oslo University Hospital
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II study of palliative radiotherapy combined with Zoledronic Acid Hydrate for metastatic bone tumor from renal cell carcinomaRenal cancerJPRN-UMIN000007836Shizuoka Cancer Center Japanese Radiation Oncology Study Group30
招募中
1 期
Phase I study for simultaneous radiochemotherapy of relapsed ovarian cancerC51-C58Malignant neoplasms of female genital organsDRKS00008552niversitätsklinikum für Strahlentherapie6
招募中
2 期
A phase II study of combination of radiotherapy and Atezolizumab/nab-paclitaxel for inoperable or recurrent PD-L1 positive triple negative breast cancerinoperable or recurrent PD-L1 positive triple negative breast cancerJPRN-jRCTs021210010Suzuki Yoshiyuki20
终止
1 期
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung CancerLocally Advanced Non-Small Cell Lung CancerNCT00614484Loma Linda University28
已完成
2 期
A Phase II trial of S-1 and concurrent radiotherapy for locally advanced pancreatic cancerJPRN-UMIN000000486Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital60